JMJD3 upregulates ALOX5 to drive malignancy and concomitant ferroptosis sensitivity in gastric cancer
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-04 03:49
摘要：
JMJD3 is identified as a key regulator in gastric cancer, promoting malignancy and chemotherapy resistance by upregulating ALOX5. This study demonstrates that JMJD3 enhances stemness characteristics in gastric cancer cells, making them more resistant to treatment. Importantly, the findings suggest that targeting JMJD3 could improve the efficacy of existing therapies by increasing sensitivity to ferroptosis inducers, offering a promising avenue for future gastric cancer treatments.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+核心领域符合度
business_impact
0.5分+商业影响力
scientific_rigor
1.5分+数据支撑的科学性
timeliness_innovation
1.5分+时效性与创新性
investment_perspective
2.5分+BOCG投资视角
market_value_relevance
1.0分+市场价值相关性
team_institution_background
0.5分+团队与机构背景
technical_barrier_competition
0.5分+技术壁垒与竞争格局
关键证据
JMJD3 is highly expressed in gastric cancer tissues and correlates with chemotherapy resistance.
Targeting JMJD3 may provide a novel therapeutic strategy for overcoming chemotherapy resistance.
ALOX5 upregulation due to JMJD3 enhances sensitivity to ferroptosis inducers.
真实性检查
否
AI评分总结
JMJD3 is identified as a key regulator in gastric cancer, promoting malignancy and chemotherapy resistance by upregulating ALOX5. This study demonstrates that JMJD3 enhances stemness characteristics in gastric cancer cells, making them more resistant to treatment. Importantly, the findings suggest that targeting JMJD3 could improve the efficacy of existing therapies by increasing sensitivity to ferroptosis inducers, offering a promising avenue for future gastric cancer treatments.